Skip to main content
BMYBristol-Myers Squibb CompanySell6.2·$68.09+0.64%

Bristol-Myers Squibb (BMY) Q2 2026 earnings — TrendMatrix coverage

BEAT+27.7% vs estimateEPS $2.04 vs $1.60 estVerdict Data IssueHold

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure

Event detail · Q2 2026

Key numbers

Reported EPS
$2.04
Estimate
$1.60
Surprise
+27.7%
Revenue (period 2026-06-30)
$12.97B
Score at report (before → after)
6.66.7/10

Revenue source: xbrl.

Report record · Q2 2026

How the report landed

Bristol-Myers Squibb (BMY) beat the $1.60 estimate with diluted EPS of $2.04 — a large 27.7% upside surprise. TrendMatrix's engine moved from Data Issue (6.6/10) to Hold at 6.7/10 after the report.

Current read · as of 2026-09-04

Where TrendMatrix's rating stands now

TrendMatrix currently rates BMY Sell at 6.2/10.

4 of the last 4 quarters beat the estimate; this quarter's +27.7% surprise compares with a +12.8% four-quarter average. Next scheduled report: 2026-10-29.

What supports the rating

  • V7 quality resilience bonus: +0.2 (Q=7.7 in RISK_OFF)
  • Sector modifier (Healthcare): +0.5

What argues against it

  • Concentration risk — Geographic: United States (69.0%)
  • Analyst target reached - limited upside remaining
  • Near 52-week high (0.8% away)

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$68.09
Price target
$78.30
Stop
$65.09
Upside to target
+15.0%

The stock trades at 14.7× trailing but 10.3× forward earnings — consensus estimates already build in a substantial earnings recovery.

Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.

Healthcare context

BMY at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Drug Manufacturers - General
Market cap
$138.21B
P/E (fwd)
10.3
P/E (ttm)
14.7
52-week range
$42.52$68.64
Off 52-week high
0.8%
RSI (14)
69
Volume vs avg
0.75×
Score today
6.2/10

Earnings figures are sourced from TrendMatrix’s pipeline (EPS: existing earnings extraction; revenue: SEC XBRL company facts where available, yfinance-provisional otherwise). Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home Stocks BMY Earnings Q2 2026 earnings